Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone conference call.)

Contact Person: Gillian Einstein, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5198, MSC 7850, Bethesda, MD 20817. (301) 435–4433. *einsteig@csr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 29, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–30956 Filed 12–6–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: ''Coil for Transcranial Magnetic Stimulation''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is a public notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the inventions embodied in:

Employee Invention Report E–223–00/0, ''Coil for Magnetic Stimulation,'' PCT Application No. PCT/US01/50737 by Zangen *et al.*

to BrainGate, Inc., having a place of business at 25883 Goose Neck Rd, Royal Oak, MD 21662.

The United States of America is the assignee to the patent rights of these inventions.

The contemplated exclusive license may be restricted to the fields of Transcranial Magnetic Stimulation (TMS) therapies and apparatus.

DATES: Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before February 7, 2003, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Dale D. Berkley, Ph.D., J.D. Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–5019; Facsimile: (301) 402–0220; E-mail: *berkleyd@od.nih.gov.* A signed confidential disclosure agreement will be required to receive copies of the patent application.

SUPPLEMENTARY INFORMATION: The invention is a magnetic stimulator that is placed in contact with the head of a subject to magnetically stimulate the brain. The device has applications in the treatment of cardiovascular or neurophysiological conditions, and may be of particular utility in the treatment of disorders associated with deep regions of the brain, such as drug addiction and depression. The unique coil shape of the stimulator is designed to target the nucleus accumbens, a region deep within the brain associated with the biological mechanism underlying drug abuse. Deep regions of the brain are also implicated in depressive disorders, and this coil is likely to offer an improvement in the transcranial magnetic stimulation therapy currently being tested for treatment of depression.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: November 29, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–30959 Filed 12–5–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

The National Toxicology Program (NTP) Center for the Evaluation of Risks to Human Reproduction (CERHR): Availability of Draft Expert Panel Reports on Ethylene Glycol and Propylene Glycol, Request for Public Comment, and Expert Panel Meeting Planned

Summary: The NTP CERHR announces:

1. The availability of the draft expert panel reports on ethylene glycol and propylene glycol and solicits written public comments on the reports January 23, 2003.

2. An expert panel meeting on February 11–13, 2003, at the Holiday Inn Old Town Select, Alexandria, Virginia and invites the public to present oral comments at this meeting.

Questions about the draft expert panel reports, submission of public comments, and the expert panel meeting should be directed to Dr. Michael Shelby, CERHR director (contact information below).

Draft Expert Panel Reports on Ethylene Glycol and Propylene Glycol Available

The CERHR announces the availability of draft expert panel reports on ethylene glycol (CASRN 107–21–1) and propylene glycol (CASRN 57–55–6). Most ethylene glycol is used as a chemical intermediate in the production of polyester compounds. There is widespread public exposure to ethylene glycol due to its use as automotive antifreeze and as a de-icer for aircraft. The toxicology database on ethylene glycol includes recent mechanistic data and occupational exposure information. Propylene glycol, similar in structure to ethylene glycol, is used as an antifreeze and de-icing solution and in various paints and coatings. Propylene glycol is approved for use in foods, drugs, and cosmetics.

Each draft expert panel report has the following sections:

1.0 Chemistry, Use, and Human Exposure
2.0 General Toxicological and Biological Effects
3.0 Developmental Toxicity Data
4.0 Reproductive Toxicity Data
5.0 Summary, Conclusions, and Critical Data Needs (to be written at expert panel meeting)

Sections 1–4 will be available to the public by December 4, 2003, and can be obtained electronically on the CERHR web site (*http://cerhr.niehs.nih.gov*) or in hard copy by contacting Dr. Michael Shelby, Director CERHR (NIEHS, 79